Wualex [Public domain] via Wikimedia Commons
After successfully preventing and reversing vitiligo in two different mouse models, I. Caroline Le Poole (Loyola University Chicago, Maywood, IL) and her colleagues have applied for a patent and are seeking regulatory approval and funding to carry out a clinical trial. The basis of their new treatment is a mutant version of the heat-shock protein HSP70i, previously implicated in the development of vitiligo.
Lab Anim. (NY) 42, 110 (2013).
view full text (login required)